Neuromodulation

MRI-guided SAINT TMS aims to remit treatment-resistant depression in days.

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.

A multicenter study tests SAINT TMS for postpartum depression.

Explore how TMS offers a World Anti-Doping Agency-safe, nondrug option for athletes.

Innovative combinations of transcranial magnetic stimulation and ketamine therapy offer new hope for treatment-resistant depression, pain, and substance use disorders.

FDA approves ProlivRx, a groundbreaking at-home therapy for major depressive disorder, offering new hope for patients unresponsive to traditional treatments.

Explore how transcranial magnetic stimulation enhances athletic performance and mental health, offering innovative solutions for athletes facing psychological challenges.

Explore the transformative role of TMS in treating depression, its innovative protocols, and future advancements in psychiatric care.

At-home transcranial magnetic stimulation offers a safe, effective way to treat depression, enhancing access and reducing reliance on medications.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.

Late-life depression poses unique challenges, impacting cognitive function and requiring tailored treatment strategies for older adults.

Apathy significantly affects cognitive impairment patients, yet remains underrecognized. Discover effective assessment and treatment strategies for improved outcomes.

FDA clears accelerated deep TMS protocol for major depressive disorder, offering faster treatment with similar outcomes and fewer visits.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

A pioneer in cognitive behavior therapy shares his thoughts on a 50-year-long career.

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

A recent study found that ketamine and transcranial magnetic stimulation show promise in treating treatment-resistant depression in older adults.

Frontal lobe syndrome can present with a range of perseverative, disinhibited, overactive behaviors that do not meet traditional dementia/neurocognitive disorder criteria. Learn more here.

Clinicians should consider rTMS as an intervention to alleviate OCD symptoms, especially in those who have failed other treatments or those with comorbid depression.

An expert shares more about the recent data on NeuroStar advanced TMS. Learn more here.

Negative symptoms pose significant challenges for individuals with schizophrenia and their caregivers.

According to new data, NeuroStar Advanced TMS helped nearly 60% of adolescents with major depressive disorder.

The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression.

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.